Usana Health Sciences Inc. USNA
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Usana Health Sciences Inc. (USNA) is a healthcare company listed in the US with a market value of about $245M. In the twelve months to October 3, 2026 it had revenue of $906M and net income of -$21M, a net margin of -2.3%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 8.3, 5-year revenue growth of -4% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% above the current price.
About Usana Health Sciences
Usana Health Sciences is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $790M in 2014 to $925M in 2025, growth of about 1.4% a year. It was profitable in 10 of the last 10 years in our data. Its share count fell by 4% over three years (buybacks). It spends 1% of revenue on research and development.
Score: 2.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $906M | $925M | $855M | $921M | $999M | $1.2B | $1.1B | $1.1B | $1.2B | $1.0B | $1.0B |
| Net income | -$21M | $11M | $42M | $64M | $69M | $117M | $125M | $101M | $126M | $63M | $100M |
| Free cash flow | $30M | $9M | $51M | $56M | $94M | $108M | $145M | $110M | $141M | $111M | $104M |
| EPS (diluted) | $-1.14 | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 |
| Net margin | -2.3% | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% |
| ROIC | — | 5.2% | 6.4% | 11.3% | 15.3% | 28.2% | 27.5% | 25.9% | 31.7% | 28.8% | 30.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $22.00, 66% above the current price; targets range from $22.00 to $22.00; the consensus rating is “Strong buy”; expected EPS is $0.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Usana Health Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 96% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Usana Health Sciences pay a dividend?
Not currently.
Is Usana Health Sciences a good stock to buy?
We do not give buy or sell advice. Usana Health Sciences scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.